Analysis of human sperm karyotypes in testicular cancer patients before and after chemotherapy.
Sperm karyotype analysis was performed on testicular cancer patients before and after treatment with BEP (bleomycin, etoposide, and cisplatin). A total of 788 sperm chromosome complements was studied, 236 before chemotherapy (CT) and 552 post-CT. There was no significant difference in the total frequency of sperm chromosomal abnormalities pre-CT (10.2%) compared to post-CT (10.7%). Similarly, there were no significant differences in the frequencies of numerical abnormalities (2.5% pre-CT vs. 2.4% post-CT) or structural abnormalities (6.4% pre-CT vs. 7.4% post-CT). The percentage of X-bearing sperm was also not significantly different before (46.3%) and after CT (50.1%). The results in cancer patients were not significantly different from those in control donors. This study corroborates results from our previous analysis of these same men using multicolor fluorescence in situ hybridization for assessment of aneuploidy for chromosomes 1, 12, X, Y, and XY. Together, these two studies suggest that the sperm of men receiving BEP chemotherapy are not at increased risk of chromosomal abnormalities two or more years after treatment.
Martin
R H
RH
Department of Genetics, Alberta Children's Hospital, Calgary, Canada. renee@ach.ucalgary.ca
Ernst
S
S
Rademaker
A
A
Barclay
L
L
Ko
E
E
Summers
N
N
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001761:Bleomycin / Q000009:adverse effects; D018236:Carcinoma, Embryonal / Q000235:genetics*; D002869:Chromosome Aberrations; D002945:Cisplatin / Q000009:adverse effects; D005047:Etoposide / Q000009:adverse effects; D006801:Humans; D007621:Karyotyping; D008297:Male; D017422:Sequence Analysis, DNA; D013094:Spermatozoa / Q000648:ultrastructure*; D013736:Testicular Neoplasms / Q000188:drug therapy / Q000235:genetics*
D001761:Bleomycin; D005047:Etoposide; D002945:Cisplatin